Catalyst Event
Yuhan Corp (000100) · Earnings Release
From Akros SCHK HK-Korea Biotech Index (ASHKBIO)
4/30/2026, 12:00:00 AM
Yuhan Corp. announced Q1 2026 earnings. Consolidated revenue was KRW 526.8B (+7.2% YoY) and operating profit was KRW 8.8B (+37.3% YoY). Operating profit missed market expectations due to the delayed recognition of a milestone payment for Lazertinib. Due to the earnings miss, a ~5% price impact is expected.
Korean Translation
유한양행 2026년 1분기 실적 발표. 연결 기준 매출 5,268억(전년 동기 대비 7.2% 증가), 영업이익 88억(전년 동기 대비 37.3% 증가) 기록. 레이저티닙 관련 마일스톤 수령 지연으로 영업이익은 시장 기대치를 하회함. 실적 부진에 따라 약 5%의 주가 하락이 예상됨.
Related Recent Events
Samchundang Pharm Co Ltd (000250) · Other
Extraordinary shareholders' meeting to appoint a former Financial Supervisory Service (FSS) official as a new outside director on June 30, 2026. Low importance is estimated as board changes typically have minimal immediate price impact, scheduled.
6/30/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Earnings Release
The company's quarterly earnings report is scheduled for May 18, 2026; a 5-10% price impact is estimated based on historical volatility, scheduled.
5/18/2026, 12:00:00 AM
Samchundang Pharm Co Ltd (000250) · Earnings Release
Q1 2026 earnings release on May 18, 2026. Low importance is estimated as the announcement of the release date itself usually results in minimal price movement, scheduled.
5/18/2026, 12:00:00 AM
Celltrion Inc (068270) · Earnings Release
Celltrion is scheduled to announce its Q1 2026 earnings on May 8, 2026. Analysts forecast consolidated sales of approximately 1.12 trillion KRW and an operating profit of around 314 billion KRW, which is estimated to have a medium market impact (≥5%) scheduled.
5/8/2026, 12:00:00 AM
Samsung Biologics Co Ltd (207940) · Other
The company's labor union has threatened its first-ever general strike to begin on May 1, 2026, following the breakdown of wage negotiations. Analysts forecast a price impact of over 10% due to significant operational risks, expected.
5/1/2026, 12:00:00 AM
Celltrion Inc (068270) · Other
Celltrion applied for marketing authorization to the European Medicines Agency (EMA) for 'Herzuma SC', a subcutaneous formulation of its breast cancer biosimilar Trastuzumab, on April 30, 2026. This first-in-class formulation is estimated to have a high market impact (≥10%) due to its significant competitive advantage.
4/30/2026, 12:00:00 AM